Business Context and Reporting Period
Company: Sight Sciences, Inc. (SGHT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Sight Sciences develops interventional ophthalmic technologies for glaucoma and dry eye disease. The company operates two segments: Interventional Glaucoma (OMNI and SION products) and Interventional Dry Eye (TearCare system). It is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $77,363 | $79,866 |
| Gross Profit | $66,666 | $68,285 |
| Gross Margin | 86.2% | 85.5% |
| Net Loss | $(38,426) | $(51,507) |
| Operating Expenses | $103,765 | $118,817 |
| Cash and Cash Equivalents (Year End) | $91,965 | $120,357 |
| Long-Term Debt (Principal) | $40,000 | $40,000 |
| Accumulated Deficit | $(384,723) | $(346,297) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3.1% to $77.4 million. Interventional Glaucoma revenue remained flat ($75.7M vs $75.9M), while Interventional Dry Eye revenue dropped 58.7% to $1.6M due to a strategic shift to focus on establishing reimbursed market access for TearCare.
- Cost Reductions: Operating expenses decreased 12.7% to $103.8 million, driven by a targeted restructuring plan in Q3 2025 that reduced headcount by approximately 20% and cut R&D and SG&A spending.
- Improved Loss Profile: Net loss improved by 25.4% to $38.4 million, primarily due to reduced operating expenses and the absence of a $2.0 million loss on debt extinguishment recorded in 2024.
- Margin Pressure: While overall gross margin improved slightly to 86.2%, the Interventional Glaucoma segment margin decreased to 86.8% (from 87.6%) due to tariffs on Chinese imports and higher overhead costs per unit.
- Reimbursement Environment: New Medicare Administrative Contractor (MAC) Local Coverage Determinations (LCDs) effective in late 2024 restricted coverage for multiple MIGS procedures, impacting Glaucoma volumes. Conversely, two MACs established pricing for TearCare in late 2025.
Guidance, Outlook, and Risks
- Liquidity: Management expects cash and cash equivalents ($92.0M) plus available borrowings under the Hercules Loan Agreement to fund operations for at least the next 12 months.
- Debt Facility: The company has a $65.0M senior secured term loan with Hercules Capital. $40.0M is currently drawn. The interest-only period was extended to February 1, 2027, via a September 2025 amendment.
- Strategic Focus:
- Glaucoma: Expanding the "Standalone Market" for OMNI (pseudophakic patients) and defending reimbursement against competitive pressures and MAC restrictions.
- Dry Eye: Scaling commercial infrastructure in jurisdictions where TearCare reimbursement has been established (Novitas and FCSO MACs) and pursuing broader coverage.
- Key Risks:
- Reimbursement: Continued uncertainty regarding Medicare and commercial payor coverage policies for both Glaucoma and Dry Eye procedures.
- Supply Chain & Tariffs: Significant reliance on single-source manufacturing in China. U.S. tariffs imposed in 2025 have negatively impacted gross margins; the company is diversifying manufacturing for 2026.
- Legal: Ongoing patent litigation against Alcon regarding the Hydrus Microstent. A $34M jury verdict was awarded in April 2024, but the judgment is subject to appeal and potential patent reexamination.
- Profitability: The company has a history of significant losses and expects to incur losses for the foreseeable future.
Investor Verification Checklist
- Reimbursement Status: Verify the current status of Medicare coverage determinations (LCDs) for MIGS procedures and the expansion of TearCare reimbursement beyond the Novitas and FCSO jurisdictions.
- Tariff Impact: Assess the timeline and cost implications of the company's plan to diversify manufacturing away from China to mitigate U.S. tariff impacts on gross margins.
- Legal Proceedings: Monitor the outcome of the Alcon patent litigation appeal and the USPTO reexamination proceedings, which could impact the collectability of the $34M verdict.
- Cash Burn Rate: Review the company's ability to maintain liquidity given the $40M debt obligation and continued operating losses, specifically the timeline for achieving profitability.
- Restructuring Execution: Confirm that the cost savings from the 20% workforce reduction are sustainable and not offset by increased investment in commercial scaling.